FiercePharmaMarketing will now publish every Monday and Wednesday

Rebecca Friend

We've seen remarkable growth in our readership since the launch of FiercePharmaMarketing last January. Our email readership now reaches over 30,000 pharma marketing professionals and is one of the Life Sciences group's fastest growing reports. With that growth comes higher expectations from you, the reader, and I am pleased to announce that we will be expanding our coverage to a twice-weekly email report. Starting today, you will receive FiercePharmaMarketing every Monday and Wednesday.

I hope you enjoy our added coverage. We are always interested to hear from you, our readers. Please reach out to let us know how we are doing. -- Rebecca Friend (Twitter | email)

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

With drug-resistant bacteria on the rise, antibiotics have struggled to keep up. But with an FDA nod for Nabriva's Xenleta, some of that may change.

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.